19 February 2021
The rolling review will assess CVnCoV’s efficacy and immunogenicity data as it becomes available, speeding the decision process for an eventual marketing authorisation application.
The European Medicines Agency (EMA)’s Committee for Human Medicinal Products (CHMP) has started a rolling review of CureVac AG’s COVID-19 vaccines, CVnCoV.
The review was initiated because preliminary laboratory studies and early clinical trial results suggest the vaccine triggers the production of antibodies and immune cells that target SARS-CoV-2, the virus that causes COVID‑19.
The review will sequentially review data as it becomes available, starting with the preclinical and early phase evidence currently submitted. In contrast to a traditional marketing authorisation application, in which all data on a medicine’s or vaccine’s effectiveness, safety and quality and all required documents must be ready at the start of the evaluation.
Ongoing trials are continuing to evaluate the vaccine’s safety, immunogenicity and effectiveness against COVID-19. EMA will evaluate data from these and other clinical trials as they become available.
The rolling review will continue until the CHMP decides that sufficient data is available for a formal marketing authorisation application. As a result of the work undertaken in the rolling review, it should take less time than normal to evaluate such an application.
EMA will assess the vaccine’s compliance with the usual standards for effectiveness, safety and pharmaceutical quality within the rolling review process.
CVnCoV is an mRNA vaccine which encodes the SARS-CoV-2 Spike (S) protein. The mRNA sequence is formulated in minute lipid particles to prevent it from being broken down too quickly.
When a person receives the vaccine, some of their cells will use the mRNA molecules to temporarily produce the S protein. This activates the person’s immune system, priming it to respond more quickly to a subsequent SARS-CoV-2 infection.
The mRNA from the vaccine does not persist in the body, it is broken down shortly after vaccination.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024